WO2000020587A3 - Cancer associated antigens and uses therefor - Google Patents

Cancer associated antigens and uses therefor Download PDF

Info

Publication number
WO2000020587A3
WO2000020587A3 PCT/US1999/022873 US9922873W WO0020587A3 WO 2000020587 A3 WO2000020587 A3 WO 2000020587A3 US 9922873 W US9922873 W US 9922873W WO 0020587 A3 WO0020587 A3 WO 0020587A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
molecules
cancer associated
cancer
peptides
Prior art date
Application number
PCT/US1999/022873
Other languages
French (fr)
Other versions
WO2000020587A2 (en
Inventor
Yuichi Obata
Ivan Gout
Ozlem Tureci
Ugar Sahin
Michael Pfreundschuh
Matthew J Scanlan
Elisabeth Stockert
Yao-Tseng Chen
Lloyd J Old
Elke Jager
Alex Knuth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/166,350 external-priority patent/US6440663B1/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to EP99953017A priority Critical patent/EP1117791A2/en
Priority to JP2000574682A priority patent/JP2003517274A/en
Priority to CA002344995A priority patent/CA2344995A1/en
Priority to KR1020017004344A priority patent/KR20010083890A/en
Priority to AU65055/99A priority patent/AU6505599A/en
Publication of WO2000020587A2 publication Critical patent/WO2000020587A2/en
Publication of WO2000020587A3 publication Critical patent/WO2000020587A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
PCT/US1999/022873 1998-10-05 1999-10-04 Cancer associated antigens and uses therefor WO2000020587A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99953017A EP1117791A2 (en) 1998-10-05 1999-10-04 Cancer associated antigens and uses therefor
JP2000574682A JP2003517274A (en) 1998-10-05 1999-10-04 Cancer-associated antigens and uses thereof
CA002344995A CA2344995A1 (en) 1998-10-05 1999-10-04 Cancer associated antigens and uses therefor
KR1020017004344A KR20010083890A (en) 1998-10-05 1999-10-04 Cancer Associated Antigens and Uses Therefor
AU65055/99A AU6505599A (en) 1998-10-05 1999-10-04 Cancer associated antigens and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16630098A 1998-10-05 1998-10-05
US09/166,350 1998-10-05
US09/166,300 1998-10-05
US09/166,350 US6440663B1 (en) 1998-10-05 1998-10-05 Renal cancer associated antigens and uses therefor

Publications (2)

Publication Number Publication Date
WO2000020587A2 WO2000020587A2 (en) 2000-04-13
WO2000020587A3 true WO2000020587A3 (en) 2000-10-12

Family

ID=26862150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022873 WO2000020587A2 (en) 1998-10-05 1999-10-04 Cancer associated antigens and uses therefor

Country Status (7)

Country Link
EP (1) EP1117791A2 (en)
JP (1) JP2003517274A (en)
KR (1) KR20010083890A (en)
CN (1) CN1367830A (en)
AU (1) AU6505599A (en)
CA (1) CA2344995A1 (en)
WO (1) WO2000020587A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818419B2 (en) * 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
US6774223B2 (en) * 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
ES2269430T3 (en) * 2000-08-04 2007-04-01 Ludwig Institute For Cancer Research SUPPRESSOR GEN.
DE10055285A1 (en) * 2000-11-08 2002-06-06 Deutsches Krebsforsch New markers for the diagnosis and therapy of tumors
WO2002040680A2 (en) * 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
US6965023B2 (en) 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
JP2005211023A (en) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc Method for estimating possibility of metastasis or relapse of renal cell carcinoma
JP5470848B2 (en) 2006-08-04 2014-04-16 味の素株式会社 Lung cancer evaluation method, lung cancer evaluation device, lung cancer evaluation method, lung cancer evaluation system, lung cancer evaluation program, recording medium, and information communication terminal device
JP5746811B2 (en) 2006-12-21 2015-07-08 味の素株式会社 Colorectal cancer evaluation method, colorectal cancer evaluation device, colorectal cancer evaluation method, colorectal cancer evaluation system, colorectal cancer evaluation program, and recording medium
JP5746810B2 (en) 2006-12-21 2015-07-08 味の素株式会社 Breast cancer evaluation method, breast cancer evaluation apparatus, breast cancer evaluation method, breast cancer evaluation system, breast cancer evaluation program and recording medium
CN104330571B (en) 2008-06-20 2017-09-08 味之素株式会社 The evaluation method of prostatic disorders
EP3023788B1 (en) * 2010-05-14 2020-02-12 The General Hospital Corporation Compositions of tumor specific neoantigens for use in treating tumours
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
CN113846062A (en) * 2014-07-25 2021-12-28 赛拉福柯蒂斯公司 Lentiviral vectors for regulated expression of chimeric antigen receptor molecules
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
IL255769B2 (en) 2015-05-20 2023-09-01 Broad Inst Inc Shared neoantigens
CA3028002A1 (en) * 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
JP2022512591A (en) * 2018-10-05 2022-02-07 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート Newborn screening for primary immunodeficiency, cystinosis, and Wilson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029409A2 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
WO1998048020A2 (en) * 1997-04-18 1998-10-29 Istituto Europeo Di Oncologia S.R.L. Mammalian ubiquitin-isopeptidases that control cell proliferation
WO1999018989A1 (en) * 1997-10-16 1999-04-22 Baylor College Of Medicine F-box proteins and genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
WO1996029409A2 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens
WO1998048020A2 (en) * 1997-04-18 1998-10-29 Istituto Europeo Di Oncologia S.R.L. Mammalian ubiquitin-isopeptidases that control cell proliferation
WO1999018989A1 (en) * 1997-10-16 1999-04-22 Baylor College Of Medicine F-box proteins and genes

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Database EMBL Entry HSAA24402; Accession number AA211485 02.02.1997 zn55c06.s1 Stratagene muscle 937209 Homo sapiens cDNA clone IMAGE:562090 3' similar to TR:E245548 E245548 Chromosome XII Reading frame ORF YLR097C Hillier, L. et al.; in relation to SEQ ID No. 4 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002132221, Database accession no. AA858164 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002132222, Database accession no. AA188593 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002132223, Database accession no. AI139112 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002132224, Database accession no. AA415243 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002132225, Database accession no. W00437 *
Database EMBL, 06.July 1999; Entry AF155110; Accession number AF155110 Scanlan, M.J. et al.; in relation to SEQ ID Nos. 1 and 12 *
Database EMBL, 06.July, 1999; Entry AF155114; Accession number AF155114; Scanlan, M.J. et al.; in relation to SEQ ID Nos. 4, 5, 15 and 16 *
Database EMBL; 06.07.1999; Entry AF155116; Accession number AF155116; in relation to SEQ ID No. 7 *
Database EMBL; 10.04.1997; Entry HSAB2533; Accession number AB002533; in relation to SEQ ID No. 35 *
GANSLER, T. S. ET AL.: "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival", HUMAN PATHOLOGY, vol. 28, 1997, pages 686 - 692, XP000909948 *
JIANG, C. ET AL.: "Characterization of colorectal cancer related cDNA clones obtained by subtractive hybridization screening", JOURNAL OF CANCER RESEARCH AND ONCOLOGY, vol. 123, 1997, pages 447 - 451, XP000909986 *
KAWAHARA, K. ET AL.: "Review: Potassium transport and potassium channels in the kidney tubules", JAPANESE JOURNAL OF PHYSIOLOGY, vol. 47, 1997, pages 1 - 10, XP000881680 *
NAKAMURA, T. ET AL.: "A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells", ONCOGENE, vol. 7, 1992, pages 733 - 741, XP000670282 *
RICH, B.E. AND STEITZ, J.A.: "Human acidic ribosomal phosphoproteins P0, P1 and P2: Analysis of cDNA clones in vitro synthesis and assembly", MOLECULAR AND CELLULAR BIOLOGY, vol. 7, 1987, pages 4065 - 4074, XP000909977 *
SAHIN ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 December 1995 (1995-12-01), pages 11810 - 11813, XP002091914, ISSN: 0027-8424 *
SCANLAN, M.J. ET AL.: "Antigens recognized by autologous antibody in patients with renal-cell carcinoma", INTERNATIONAL JOURNAL OF CANCER, vol. 83, 12 November 1999 (1999-11-12), pages 456 - 464, XP000867569 *
SEKI, T. ET AL.: "Cloning of the cDNA encoding a novel importin alpha homologue, Qip1: Discrimination of Qip1 and Rch1 from hSrp1 by their ability to interact with DNA helicase A1/RecQL", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, 1997, pages 48 - 53, XP000910159 *
SEMENKOVICH C F ET AL: "Human fatty acid synthase mRNA: tissue distribution, genetic mapping and kinetics of decay after glucose deprivation", JOURNAL OF LIPID RESEARCH,US,BETHESDA, MD, vol. 36, no. 7, July 1995 (1995-07-01), pages 1507 - 1521-1521, XP002105049, ISSN: 0022-2275 *
WANG, W. ET AL.: "Renal K+ channels: Structure and function", ANNUAL REVIEW OF PHYSIOLOGY, vol. 59, 1997, pages 413 - 436, XP000881688 *

Also Published As

Publication number Publication date
WO2000020587A2 (en) 2000-04-13
AU6505599A (en) 2000-04-26
JP2003517274A (en) 2003-05-27
CN1367830A (en) 2002-09-04
KR20010083890A (en) 2001-09-03
EP1117791A2 (en) 2001-07-25
CA2344995A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
WO2000020587A3 (en) Cancer associated antigens and uses therefor
BR0009323A (en) Human antibodies that bind human il-12 and methods for production
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
AU6063500A (en) Glycoprotein vi and uses thereof
BR9707379A (en) Isolated human antibody Isolated nucleic acid recombinant host cell expression vector process to synthesize a human antibody that binds to TNF Human alpha pharmaceutical composition process to inhibit human TNF activity and use of the antibody
AU7599500A (en) Novel gl50 molecules and uses therefor
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
WO2004024750A3 (en) Cd44-binding ligands
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO2002078526A3 (en) Cancer-testis antigens
EP0383129A3 (en) Pancreatic islet cell antigens obtained by molecular cloning
WO1998011221A3 (en) CAR, a novel coxsackievirus and adenovirus receptor
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO2001000874A3 (en) Cancer associated antigens and uses therefor
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2001040291A3 (en) Proteins and nucleic acids encoding the same
WO2000020586A3 (en) Renal cancer associated antigens and uses therefor
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811787.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1999 65055

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 65055/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999953017

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2344995

Country of ref document: CA

Ref document number: 2344995

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017004344

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 574682

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999953017

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017004344

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999953017

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017004344

Country of ref document: KR